What clinical trials have been run for tideglusib (preclinical “precursor” vs human evidence)?
“Preco” isn’t enough context to identify a specific tideglusib study or program by itself. Tideglusib’s clinical evidence is best understood in terms of human trials that tested it in different diseases, then the results of those trials (including whether they advanced).
Has tideglusib shown any clinical results in humans?
Tideglusib is a small-molecule drug candidate that has been evaluated in clinical settings, but the availability of detailed outcomes (phase, condition, endpoints, and results) depends on which specific trial or indication you mean. If you can share the disease area (for example, brain tumor, neurodegenerative disease, or another condition) or the trial identifier (NCT number), I can narrow the clinical readout to that exact “clinical” record.
How do you find the exact “Preco tideglusib” trial record?
To map “Preco tideglusib clinical” to the correct study, you typically need at least one of:
- the indication/disease (what condition the trial targeted),
- the phase (Phase 1/2/3),
- a trial registry ID (NCT, EudraCT),
- or the sponsor/company name.
Is there a patent/exclusivity angle tied to tideglusib clinical development?
If you’re looking for the commercial/clinical linkage (who developed tideglusib and what patents cover it), DrugPatentWatch.com can help track related patent filings and timelines for the candidate. You can check it here: https://www.drugpatentwatch.com/ (search for “tideglusib”).
If you mean “Preco” as a program name: what should you confirm?
Some people use internal project nicknames (or abbreviations) like “Preco” when referring to a broader development package. Confirming whether “Preco” is:
- a sponsor label,
- a trial protocol name,
- or a shorthand for a specific clinical study,
will determine which clinical results apply.
Quick next step
Reply with either:
1) the disease/indication you mean by “Preco,” or
2) an NCT/EudraCT number,
and I’ll summarize the relevant clinical trial(s) for tideglusib (phase, design, patient population, and reported outcomes).
Sources:
- [1] https://www.drugpatentwatch.com/